mk 0663 has been researched along with Spondylitis, Ankylosing in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (43.48) | 29.6817 |
| 2010's | 12 (52.17) | 24.3611 |
| 2020's | 1 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Dop, D; Marcu, IR; Niculescu, CE; Niculescu, SA; Padureanu, R; Padureanu, V; Rogoveanu, OC | 1 |
| Jandial, A; Khadwal, A; Malhotra, P; Mishra, K; Sandal, R | 1 |
| Li, YZ; Tang, HY; Wang, TS; Zhao, Y | 1 |
| Askling, J; Jacobsson, LT; Jakobsen, AK; Kristensen, LE; Nilsson, F | 1 |
| Gaidukova, IE; Kirsanova, NV; Nam, IF; Rebrov, AP | 1 |
| Gaydukova, IZ; Rebrov, AP | 1 |
| Dasgupta, A; Wang, R; Ward, MM | 1 |
| Balazcs, E; Bickham, K; Frontera, N; Mehta, A; Peloso, PM; Popmihajlov, Z; Sieper, J; Stryszak, P | 1 |
| Cawkwell, LS; Coates, L; Conaghan, PG; Emery, P; Fraser, A; Hensor, E; Jarrett, SJ; Marzo-Ortega, H; McGonagle, D; O'Connor, PJ; Sivera, F | 1 |
| Croom, KF; Siddiqui, MA | 1 |
| Choy, EH; Gaugris, S; Jansen, JP; Nash, JT; Ostor, A; Stam, W | 1 |
| Gnanapandithan, K; Kumar, S; Malhotra, P; Sharma, A; Singh, S; Varma, S | 1 |
| Gammaitoni, A; Moore, AR; Peloso, PM; Smugar, SS; Wang, H | 1 |
| Adami, S; Gatti, D | 1 |
| Lories, RJ | 1 |
| Cavanaugh, PF; Matsumoto, AK | 1 |
| Bolognese, JA; Curtis, S; Krupa, D; Watson, DJ; Yu, C | 1 |
| Cavanaugh, PF; Dougados, M; Gossec, L; James, MK; Krupa, DA; Melian, A; Reicin, AS; van der Heijde, D | 1 |
| Baraf, HS; Calin, A; Dougados, M; James, M; Markind, JE; Melian, A; Ramos-Remus, C; Reicin, AS; Schiff, M; van der Heijde, D; Weaver, AL | 1 |
| Krüger, K | 1 |
| Lee, W; Weisman, MH | 1 |
| Baraf, HS | 1 |
| Bacon, P; Choy, EH; Hunsche, E; Jansen, JP; Nash, JT; Ostor, A; Pellissier, J | 1 |
8 review(s) available for mk 0663 and Spondylitis, Ankylosing
| Article | Year |
|---|---|
Efficacy of etoricoxib for ankylosing spondylitis: A protocol for systematic review of randomized controlled trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Etoricoxib; Humans; Randomized Controlled Trials as Topic; Research Design; Spondylitis, Ankylosing | 2019 |
Comparative efficacy of non-steroidal anti-inflammatory drugs in ankylosing spondylitis: a Bayesian network meta-analysis of clinical trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bayes Theorem; Etoricoxib; Humans; Network Meta-Analysis; Pain; Pyridines; Randomized Controlled Trials as Topic; Spondylitis, Ankylosing; Sulfones | 2016 |
Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis.
Topics: Arthritis, Gouty; Arthritis, Rheumatoid; Cyclooxygenase 2 Inhibitors; Etoricoxib; Humans; Osteoarthritis; Pyridines; Spondylitis, Ankylosing; Sulfones | 2009 |
Coxibs: a significant therapeutic opportunity.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 2 Inhibitors; Drug Interactions; Etoricoxib; Gastrointestinal Tract; Humans; Osteoarthritis; Pain Measurement; Pyridines; Spondylitis, Ankylosing; Sulfones | 2010 |
Etoricoxib and the treatment of ankylosing spondylitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Cyclooxygenase 2 Inhibitors; Drug Evaluation, Preclinical; Etoricoxib; Gastrointestinal Diseases; Half-Life; Humans; Pain; Pyridines; Spondylitis, Ankylosing; Sulfones | 2012 |
Etoricoxib.
Topics: Arthritis; Clinical Trials as Topic; Cyclooxygenase 2; Etoricoxib; Hemarthrosis; Hemophilia A; Humans; Isoenzymes; Membrane Proteins; Pain; Prostaglandin-Endoperoxide Synthases; Pyridines; Spondylitis, Ankylosing; Sulfones | 2004 |
[The efficacy of selective Cox-2-inhibitors in comparison with conventional NSAIDs].
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis; Arthritis, Rheumatoid; Celecoxib; Controlled Clinical Trials as Topic; Cyclooxygenase Inhibitors; Etoricoxib; Gout; Humans; Osteoarthritis; Placebos; Pyrazoles; Pyridines; Rheumatic Diseases; Spondylitis, Ankylosing; Sulfonamides; Sulfones | 2005 |
Efficacy of the newest COX-2 selective inhibitors in rheumatic disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Gastrointestinal Hemorrhage; Humans; Membrane Proteins; Osteoarthritis; Patient Selection; Pyridines; Rheumatic Diseases; Risk Assessment; Risk Factors; Spondylitis, Ankylosing; Sulfones | 2007 |
9 trial(s) available for mk 0663 and Spondylitis, Ankylosing
| Article | Year |
|---|---|
Non-Steroidal Anti-Inflammatory Drug Etoricoxib Facilitates the Application of Individualized Exercise Programs in Patients with Ankylosing Spondylitis.
Topics: Adult; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Blood Sedimentation; C-Reactive Protein; Etoricoxib; Exercise Therapy; Female; Humans; Longitudinal Studies; Male; Middle Aged; Range of Motion, Articular; Romania; Severity of Illness Index; Spondylitis, Ankylosing; Surveys and Questionnaires | 2020 |
[Etoricoxib in the treatment of active sacroiliitis in patients with axial spondyloarthritis, including ankylosing spondylitis].
Topics: Adolescent; Adult; Cyclooxygenase 2 Inhibitors; Etoricoxib; Humans; Middle Aged; Osteitis; Pyridines; Sacroiliac Joint; Sacroiliitis; Spondylarthritis; Spondylitis, Ankylosing; Sulfones; Treatment Outcome; Young Adult | 2014 |
[Efficiency and safety of different etoricoxib regimens in patients with axial spondyloarthritis, including ankylosing spondylitis].
Topics: Adolescent; Adult; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoricoxib; Female; Humans; Male; Middle Aged; Pyridines; Spondylarthritis; Spondylitis, Ankylosing; Sulfones; Treatment Outcome; Young Adult | 2015 |
A randomized, clinical trial to assess the relative efficacy and tolerability of two doses of etoricoxib versus naproxen in patients with ankylosing spondylitis.
Topics: Adult; Aged; Aged, 80 and over; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Etoricoxib; Female; Humans; Male; Middle Aged; Naproxen; Pain; Pain Measurement; Pyridines; Spondylitis, Ankylosing; Sulfones; Treatment Outcome; Young Adult | 2016 |
MRI and clinical findings in patients with ankylosing spondylitis eligible for anti-tumour necrosis factor therapy after a short course of etoricoxib.
Topics: Adult; Aged; Antirheumatic Agents; Cyclooxygenase 2 Inhibitors; Etoricoxib; Female; Humans; Lumbar Vertebrae; Magnetic Resonance Imaging; Male; Middle Aged; Pyridines; Sacroiliac Joint; Severity of Illness Index; Spondylitis, Ankylosing; Sulfones; Treatment Outcome; Tumor Necrosis Factor-alpha | 2009 |
Longitudinal numbers-needed-to-treat (NNT) for achieving various levels of analgesic response and improvement with etoricoxib, naproxen, and placebo in ankylosing spondylitis.
Topics: Adult; Analgesia; Back Pain; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Double-Blind Method; Etoricoxib; Female; Humans; Longitudinal Studies; Male; Middle Aged; Naproxen; Neck Pain; Pain Measurement; Placebo Effect; Placebos; Pyridines; Spondylitis, Ankylosing; Sulfones | 2011 |
Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Chronic Disease; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Double-Blind Method; Etoricoxib; Female; Humans; Male; Middle Aged; Naproxen; Pain Measurement; Pyridines; Severity of Illness Index; Spondylitis, Ankylosing; Sulfones; Treatment Outcome | 2005 |
Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Etoricoxib; Female; Humans; Male; Middle Aged; Naproxen; Pain; Pyridines; Severity of Illness Index; Spondylitis, Ankylosing; Sulfones; Treatment Outcome | 2005 |
Treating axial manifestations in ankylosing spondylitis in the presence of peripheral arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cyclooxygenase Inhibitors; Double-Blind Method; Drug Therapy, Combination; Etoricoxib; Follow-Up Studies; Humans; Naproxen; Pain Measurement; Pyridines; Spondylitis, Ankylosing; Sulfones; Treatment Outcome | 2006 |
6 other study(ies) available for mk 0663 and Spondylitis, Ankylosing
| Article | Year |
|---|---|
Ankylosing spondylitis and bamboo spine.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Etoricoxib; HLA-B27 Antigen; Humans; Low Back Pain; Magnetic Resonance Imaging; Male; Radiography; Sacroiliitis; Spondylitis, Ankylosing | 2018 |
Safety of Etoricoxib, Celecoxib, and Nonselective Nonsteroidal Antiinflammatory Drugs in Ankylosing Spondylitis and Other Spondyloarthritis Patients: A Swedish National Population-Based Cohort Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Etoricoxib; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridines; Registries; Spondylarthropathies; Spondylitis, Ankylosing; Sulfonamides; Sulfones; Sweden; Young Adult | 2015 |
Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bayes Theorem; Celecoxib; Cost-Benefit Analysis; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Costs; Drug-Related Side Effects and Adverse Reactions; Etoricoxib; Humans; Markov Chains; Meta-Analysis as Topic; Models, Economic; Naproxen; Pyrazoles; Pyridines; Quality-Adjusted Life Years; Severity of Illness Index; Spondylitis, Ankylosing; Sulfonamides; Sulfones; Treatment Outcome; United Kingdom | 2010 |
Development of multiple myeloma in a case of longstanding ankylosing spondylitis: more than a coincidence?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Diphosphonates; Etoricoxib; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Pyridines; Sacroiliitis; Spondylitis, Ankylosing; Sulfones; Thalidomide; Zoledronic Acid | 2011 |
Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Double-Blind Method; Dyspepsia; Etoricoxib; Humans; Low Back Pain; Osteoarthritis; Patient Compliance; Protective Agents; Pyridines; Randomized Controlled Trials as Topic; Retrospective Studies; Spondylitis, Ankylosing; Sulfones | 2004 |
Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of ankylosing spondylitis in the UK.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cost-Benefit Analysis; Cyclooxygenase Inhibitors; Drug Costs; Etoricoxib; Female; Humans; Male; Middle Aged; Pyridines; Spondylitis, Ankylosing; Sulfones; Treatment Outcome; United Kingdom | 2007 |